Physician profile
Sandro Sinatora
NPI 1568558781
$3,564.73
in general payments reported to CMS, 2019-2025
37 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $897 · 2020: $775 · 2021: $769 · 2022: $356 · 2023: $351 · 2024: $191 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $767.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $468.85 | 2019-2023 | Ozempic, Rybelsus |
| Amgen INC. | $419.19 | 2019-2024 | Evenity, Prolia, Repatha |
| Abbott Laboratories | $376.51 | 2019-2025 | Freestyle Libre 3 |
| Sunovion Pharmaceuticals INC. | $324.99 | 2019-2021 | |
| Radius Health, INC. | $219.98 | 2019-2023 | Tymlos |
| Pfizer INC. | $188.34 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $174.57 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $161.12 | 2023-2025 | |
| Abbvie INC. | $154.13 | 2020-2025 | |
| Amarin Pharma, INC. | $104.59 | 2019-2021 | |
| Lilly USA, LLC | $87.18 | 2019-2023 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $69.26 | 2019-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Currax Pharmaceuticals LLC | $65.57 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $63.48 | 2020-2023 | Farxiga |
| Astellas Pharma US INC | $60.11 | 2019-2020 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandro Sinatora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.